[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345503-105":59,"doc-detail-345503-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","identification-of-brca2-likely-germline-pathogenic-variants-in-patients-with-multiple-primary-lung-adenocarcinomas","Identification of BRCA2 Likely Germline Pathogenic Variants in Patients with Multiple Primary Lung Adenocarcinomas","","Genetic risk models have clarified germline pathogenic variants in some malignancies, but their clinical relevance in lung cancer remains uncertain. This study evaluated whether germline pathogenic variants contribute to lung cancer etiology in patients with multiple primary lung cancers. A targeted panel covering 143 cancer-related genes was used to analyze 26 lung adenocarcinoma tumors from 11 patients, integrating mutation profiles for tumor classification. Shared variants across lesions and adjacent tissues were validated by Sanger sequencing as likely germline or somatic alterations. Results identified likely germline BRCA2 truncating variants and additional variants of uncertain significance, and broader testing in additional LUAD cases supported BRCA2 involvement. Overall, BRCA2 germline pathogenic variants may represent candidate pathogenic drivers and future therapeutic targets for LUAD.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/identification-of-brca2-likely-germline-pathogenic-variants-in-patients-with-multiple-primary-lung-adenocarcinomas/345503/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/identification-of-brca2-likely-germline-pathogenic-variants-in-patients-with-multiple-primary-lung-adenocarcinomas/345503.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the study’s main objective?","Question",{"text":113,"@type":114},"The study aimed to clarify how likely germline pathogenic variants (GPVs) may contribute to the etiology of lung cancer, particularly in patients with multiple primary lung cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were tumor lesions classified in the analysis?",{"text":118,"@type":114},"Tumor classification was based on integrated evaluation of mutation profiles, followed by validation of variants shared among lesions using Sanger sequencing to distinguish likely germline from somatic mutations.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the results show regarding BRCA2?",{"text":122,"@type":114},"Among cases with shared variants across lesions, one patient carried a novel truncating BRCA2 variant, and additional analysis of other LUAD cases identified another truncating BRCA2 variant in one case without typical driver mutations.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},345503,1790116425,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[http://doi.org/10.32604/or.2026.078309](http://doi.org/10.32604/or.2026.078309)  \nARTICLE  \nIdentification of BRCA2 Likely Germline Pathogenic Variants in Patients with Multiple Primary Lung Adenocarcinomas  \nDat Quoc Tran 1, Mayu Takeda2, Eiji Sugihara2, Tetsuya Tsukamoto2,3,  \nYasushi Hoshikawa4 , Yasuyoshi Mizutani 1 , Kazuya Shiogama5, Naoya Asai6 , Atsuko Niimi 1, Makoto Sumitomo2 , Hideyuki Saya2 and Motoshi Suzuki 1, *  \n1Department of Molecular Oncology, Fujita Health University, Toyoake, Japan  \n2 Oncology Innovation Center, Fujita Health University, Toyoake, Japan  \n3Department of Diagnostic Pathology, Fujita Health University, Toyoake, Japan  \n4Department of Thoracic Surgery, Fujita Health University, Toyoake, Japan  \n5Department of Pathology and Cytopathology, Fujita Health University, Toyoake, Japan  \n6Department of Pathology, Fujita Health University, Toyoake, Japan  \n*[Corresponding Author: Motoshi Suzuki. Email: motosuzu@fujita-hu.ac.jp](Corresponding Author: Motoshi Suzuki. Email: motosuzu@fujita-hu.ac.jp)[ ](Corresponding Author: Motoshi Suzuki. Email: motosuzu@fujita-hu.ac.jp)[Received: 29 December 2025](Received: 29 December 2025); [Accepted: 17 March 2026](Accepted: 17 March 2026); [Published: 21 May 2026](Published: 21 May 2026)  \nABSTRACT: Objectives: Genetic risk models have substantially advanced our understanding of germline pathogenic variants (GPVs) in some malignancies, whereas their clinical significance in lung cancer remains unclear. The present study aimed to better understand potential contribution of GPVs to lung cancer etiology. Methods: A targeted sequencing panel of 143 cancer-related genes was applied to analyze 26 distinct lung adenocarcinoma (LUAD) tumors from 11 patients histopathologically diagnosed with multiple primary lung cancers (MPLC) . Tumor classification was performed through integrated evaluation of mutation profiles, and variants shared among tumor lesions were further validated as likely germline or somatic mutations using Sanger sequencing. Results: Mutation profiles were compared to reveal clonal relationships among lesions in each patient. Nine of the 11 cases (81.8%) were classified as MPLC, 1/11 (9.1%) as intrapulmonary metastasis (IM), and 1/11 (9.1%) exhibited features of both MPLC and IM. Among the nine MPLC cases, eight (88.9%) harbored matching variants across independent tumor lesions that were also detected in tumor-adjacent regions, suggesting classification as likely germline variants. Importantly, among the eight cases with shared variants, one possessed a novel truncating BRCA2 DNA repair associated (BRCA2) variant (p.N900IfsTer4), while the others harbored variants of uncertain significance (VUS) in the tumor protein p53 (TP53), caspase recruitment domain family member 11 (CARD11), platelet derived growth factor receptor beta (PDGFRB), lysine methyltransferase 2D (KMT2D), phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1), neuregulin 1 (NRG1), androgen receptor (AR), and KIT proto-oncogene, receptor tyrosine kinase (KIT ) genes. To determine whether a similar BRCA2 variant was present in other lung cancer patients, 123 LUAD cases were analyzed, and one (0.81%) possessing a truncating BRCA2 variant (p.Q1429FfsTer20) without any typical driver mutations was identified. Conclusions: BRCA2 GPVs may represent putative pathogenic mutations, and thus be potential molecular targets for future treatment ofLUAD.  \nKEYWORDS: Multiple primary lung cancer; intrapulmonary metastasis; BRCA2 DNA repair associated; germline pathogenic variants; adenocarcinoma  \n1 Introduction  \nAccording to the GLOBOCAN 2022 database, lung cancer remains the leading cancer worldwide in regard to both incidence and mortality [1] . Recent advances in imaging technology and histopathology  \nCopyright © 2026 The Authors. Published by Tech Science Press. This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and ","cbCairYa07J2EK6M","https://ap.wps.com/l/cbCairYa07J2EK6M","pdf",3821182,15,"English","# Abstract\n# Keywords\n# 1 Introduction","[{\"question\":\"What was the study’s main objective?\",\"answer\":\"The study aimed to clarify how likely germline pathogenic variants (GPVs) may contribute to the etiology of lung cancer, particularly in patients with multiple primary lung cancers.\"},{\"question\":\"How were tumor lesions classified in the analysis?\",\"answer\":\"Tumor classification was based on integrated evaluation of mutation profiles, followed by validation of variants shared among lesions using Sanger sequencing to distinguish likely germline from somatic mutations.\"},{\"question\":\"What did the results show regarding BRCA2?\",\"answer\":\"Among cases with shared variants across lesions, one patient carried a novel truncating BRCA2 variant, and additional analysis of other LUAD cases identified another truncating BRCA2 variant in one case without typical driver mutations.\"}]","Identification of BRCA2 Likely Germline Pathogenic Variants in Patients with Multiple Primary Lung Adenocarcinomas | PDF",1790057909,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce2b363e0fea2f23dff0faca30fb7e36.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ec02d01510f3e30200cff12d97b55b3.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ed0849551960d3bdf360b0ea85d8fdb.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c0ee9b969836873e9b1621d8cef82c2.webp",980,1268]